▟ Vinebot intrinsic value, daily

← back

VEEV Veeva Systems

healthcare · valued with opus medium conviction · deep-dived 2026-11-19

HOLD
Intrinsic value$158.76
Price (at call)$277.20
Margin of safety -42.7%
vs market (rating basis) -19.5%

An excellent life-sciences cloud franchise, but the price already discounts a flawless decade of compounding.

The story

Veeva is the system of record for life-sciences commercial and R&D workflows. Its moat comes from high switching costs, regulatory-grade data, and deep pharma relationships. The company is in late high-growth: the Vault platform keeps compounding, while the Salesforce-to-Vault CRM migration and competition from IQVIA and Salesforce cap upside in the commercial suite. TTM revenue of $3.46B at a 29.9% GAAP margin confirms durable operating leverage, but growth is drifting from the mid-teens toward low double digits.

I kept most of the previous drivers because the story has not changed. GAAP margin rose again, from 28.7% to 29.9%, so the target moves from 37% to 39%. That is about a 5% relative change, not a material move: non-GAAP margins already sit in the low 40s, and stock-based compensation explains the gap. Sales-to-capital edges up to 1.9 because the reported 0.48 is distorted by excess cash, and the asset-light Vault expansion needs little capital. A 12-year horizon fits a regulated-workflow franchise with a long R&D cloud runway. Even so, the market price still implies near-flawless execution well beyond these drivers.

Value drivers

Revenue growth (Y1)13.0%
Terminal growth4.0%
Forecast horizon12y
Target operating margin39.0%
Years to target margin6
Sales-to-capital1.90
Beta0.95
Failure probability2.0%
Cost of capital (WACC)8.6%
Terminal WACC8.8%

Valuation bridge

PV of explicit FCFF10.89B
PV of terminal value13.91B
Equity value25.70B
÷ shares → per share$158.76

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 3.91B 13.0% 31.4% 934.76M 236.61M 698.16M 643.02M
2 4.38B 12.2% 33.0% 1.10B 250.54M 848.54M 719.80M
3 4.88B 11.4% 34.5% 1.28B 262.18M 1.02B 795.33M
4 5.40B 10.5% 36.0% 1.48B 270.95M 1.21B 868.04M
5 5.92B 9.7% 37.5% 1.69B 276.29M 1.41B 936.34M
6 6.45B 8.9% 39.0% 1.91B 277.66M 1.64B 998.71M
7 6.97B 8.1% 39.0% 2.07B 274.63M 1.79B 1.01B
8 7.48B 7.3% 39.0% 2.22B 266.83M 1.95B 1.01B
9 7.96B 6.5% 39.0% 2.36B 254.03M 2.11B 1.01B
10 8.41B 5.6% 39.0% 2.50B 236.15M 2.26B 992.38M
11 8.81B 4.8% 39.0% 2.62B 213.25M 2.40B 971.91M
12 9.17B 4.0% 39.0% 2.72B 185.57M 2.53B 944.45M

Key risks

  • CRM share loss or price pressure from Salesforce Life Sciences Cloud and IQVIA during the Vault CRM migration
  • Pharma budget cuts, consolidation, and drug-pricing pressure (IRA, MFN) slowing seat and module growth
  • Growth decelerating to high single digits sooner than expected, compressing the premium multiple

Catalysts

  • Top-20 pharma Vault CRM go-lives and clinical platform wins that show growth can be sustained
  • Continued GAAP margin expansion plus buybacks funded from a large net-cash position

History

DatePriceIntrinsicMoSRating
2026-11-19$277.20 $158.76 -42.7% HOLD
2026-09-30$278.57 $127.03 -54.4% HOLD
2026-08-11$234.69 $44.36 -81.1% STRONG SELL
2026-06-23$159.71 $86.61 -45.8% HOLD